Skip to content


Invested in:
Calculus EIS, Calculus VCT

Genedrive is a commercial stage personalised medicine and biotechnology company developing innovative diagnostics and biomarkers alongside providing contract research services to drug development companies.

Genedrive was founded as a contract research business (”CRO”) but is now refocussing as a Point of Care molecular diagnostics company. The company has developed and launched Genedrive®: a next-generation Point of Care molecular diagnostic system providing a low cost, rapid, versatile, simple to use and robust diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications.

With the rapid global shift of healthcare to testing and treatment of COVID-19, the company has refocused part of its resources to the development of two SARS-COV-2 tests.


The successful launch of Genedrive’s TB diagnosis system in India, the appointment of an extremely experienced CEO, David Budd, and significant advances in the development of point of care Hepatitis C diagnostic systems, are extremely encouraging to us as investors, pointing to important advances in Genedrive’s areas of medical diagnostics and a bright future for the business and its investors.

Genedrive (previously called Epistem) is quoted on the Alternative Investment Market (AIM). Calculus successfully exited a previous investment in Epistem in 2014 from its EIS funds.

Latest News

genedrive signs distribution agreement with Beckman Coulter for COVID-19 PCR testing

genedrive plc, the near patient molecular diagnostics company, has announced that it has entered into a distribution agreement with Beckman Coulter Life Sciences (“Beckman Coulter”) for its Genedrive® 96 SARS-CoV-2 Kit. The agreement enables Beckman Coulter to sell and distribute genedrive’s high-throughput COVID-19 PCR Kit in the United States and Europe for use on upper respiratory … Continued

Genedrive says coronavirus test could be available in eight weeks

Genedrive, has pivoted part of its core resources towards development of two SARS-COV-2 tests, which can determine whether someone is infected with coronavirus. The first assay, already in development, is an instrument-agnostic molecular assay (the Genedrive® 96 SARS-COV-2 test) that can be performed on a variety of high throughput molecular testing platforms already installed in many … Continued

Genedrive: Antibiotic Induced Hearing Loss Assay receives CE marking

genedrive’s genetic screening test could prevent thousands of infants from needlessly going deaf. genedrive plc, the near patient molecular diagnostics company, announced that its Antibiotic Induced Hearing Loss test, the Genedrive® MT-RNR1 ID kit, has obtained CE marking. The Genedrive® MT-RNR1 ID kit will be used in critical care settings to screen babies for a … Continued

Genedrive gets approval to trial baby deafness test in NHS hospitals

Genedrive plc has received approval from the NHS Health Research Authority to start testing its Antibiotic Induced Hearing (AIHL) test in hospital trials. The AIHL test will be trialled in 1,000 patients from two large UK intensive care units in a study (PALOH) scheduled to start in November that will run for six months. This … Continued